The effect of oral Liothyronine on Aluminum phosphide poisoning

Intervention group: Drug intervention with standard therapy. Drug intervention: Liothyronine tablet 50 mcg (a single dose) by nasogastric tube, after gastric lavage. Standard therapy: oxygen 100%

Eligibility

Sex/Gender

All

Age

15 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Aluminum phosphide poisoning; admission within 12 hours of poisoning; refractory acidosis; systolic blood pressure less than 10 mm Hg with signs of tissue hypoperfusion that is resistant to treatment; refractory cardiogenic shock; persistent coma. Exclusion criteria: hypersensitivity to Liothyronine; acute myocardial infarction; untreated thyrotoxicosis; adrenal insufficiency.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Mortality rate. Timepoint: Since the entry of the patient in the study until death or discharge from the hospital. Method of measurement: Observation & Investigation.	—

Secondary

Measure	Time frame
Malondealdehyde. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Spectrophotometry.;Thyroid-stimulating hormone. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Chemiluminescence.;Total thiol molecules. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Hu colorimetric method.;Troponin I. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Immune Enzymatic Assay.;Ferrous-tripyridyltriazine complex. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Spectrophotometry.;Blood pressure. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Measured in patients by a sphygmomanometer.;Superoxide dismutase activity. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Kit.;Catalase activity. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Kit.	—

Measure

Time frame

Malondealdehyde. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Spectrophotometry.;Thyroid-stimulating hormone. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Chemiluminescence.;Total thiol molecules. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Hu colorimetric method.;Troponin I. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Immune Enzymatic Assay.;Ferrous-tripyridyltriazine complex. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Spectrophotometry.;Blood pressure. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Measured in patients by a sphygmomanometer.;Superoxide dismutase activity. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Kit.;Catalase activity. Timepoint: Beginning of the study (baseline), 12 to 24 hours after inclusion. Method of measurement: Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadhadi Goharbari

Tehran University of Medical Sciences

goharbari@yahoo.com m-goharbari@razi.tums.ac.ir+98 21 6695 9078

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026